Peripheral T-cell lymphoma, not otherwise specified
Clinical trials for Peripheral T-cell lymphoma, not otherwise specified explained in plain language.
Never miss a new study
Get alerted when new Peripheral T-cell lymphoma, not otherwise specified trials appear
Sign up with your email to follow new studies for Peripheral T-cell lymphoma, not otherwise specified, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lymphoma drug duvelisib tested after transplant – trial ends early
Disease control Stopped earlyThis phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full resul…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control Stopped earlyThis early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase 1/2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC